Spots Global Cancer Trial Database for A Study of Chidamide With AZA in MRD Positive AML After Transplant

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of Chidamide With AZA in MRD Positive AML After Transplant

Official Title: A Study of Chidamide With AZA in MRD Positive AML After Transplant

Study ID: NCT06066905

Conditions

AML, Adult

Minimal Residual Disease

Interventions

chidamide and azacitidine

Study Description

Brief Summary: acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.

Detailed Description: Investigators proposed Chidamide combined with azacitidine as the prospective treatment for MRD-positive AML patients before and after transplantation, hoping to reduce the recurrence rate of transplantation and improve the transplantation effect. The efficacy and safety of the method will be verified by this clinical study.